HCV Antivirals Race to Market - Gilead, AbbVie, Janssen, Boehringer Ingelheim and Bristol-Myers Squibb

 Just In
March 2014
Hepatitis C: Treat Now Or Wait?
To usher in March, we have a collection of slides which offer SVR rates on both FDA approved and investigational HCV agents, including interferon-free regimens in late stage clinical trials. A few other  topics touch on off-label use by combining two newly approved drugs, terminology used to determine treatment response and links to relevant information.
The slide-set is best viewed in full screen mode, please click here to begin. 

Related-
Bristol-Myers Daclatasvir Hepatitis C Treatment to Get Faster Review by the European Medicines Agency

Daclatasvir and Sofosbuvir: New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

AbbVie Amazing All-oral Regimen: 100--96 percent cure rates mostly in 12weeks even in patients w-cirrhosis 

Gilead Files for U.S. Approval:Ledipasvir/Sofosbuvir Fixed-Dose Combo For Genotype 1 Hepatitis C 

ISSUE: FEBRUARY 2014 | VOLUME: 65:2 

Source - Gastroenterology & Endoscopy News

by Kate O'Rourke

Boston—Over the next five years, a whirlwind of new direct-acting antiviral agents (DAAs) for hepatitis C are expected to get the green light from the FDA. The recent approval of simeprevir (Olysio, Janssen) and sofosbuvir (Sovaldi, Gilead)–containing regimens is only the tip of the iceberg.

“There are multiple, oral, interferon [IFN]-free DAA regimens in late-stage clinical trials with high SVR [sustained virologic response] rates,” said Mark Sulkowski, MD, medical director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology & Hepatology and professor of medicine at the Johns Hopkins School of Medicine, in Baltimore.

These include the Gilead-based regimen of sofosbuvir plus ledipasvir, with or without GS-9669; AbbVie’s ABT450/r plus ABT267 and ABT333; Boehringer Ingelheim’s faldaprevir plus deleobuvir, with or without PPI-668; Janssen’s simeprevir and samatasvir plus TMC647055/r; and Merck’s MK-8742 plus MK-5172. At press time, Bristol-Myers Squibb was in the process of submitting a regulatory filing for either daclatasvir plus asunaprevir, or this combination plus BMS 791325..............
Continue reading.........